Comprehensive real-time dashboard tracking breakthrough cancer vaccine development. Monitor mRNA vaccines, personalized immunotherapy, and revolutionary treatments across melanoma, pancreatic cancer, and 15+ cancer types.
First-in-human safety testing, dose-finding, and preliminary immunogenicity assessment in 20-80 patients
Expanded safety and efficacy evaluation, biomarker validation, and optimal dosing in 100-300 patients
Confirmatory efficacy trials with survival endpoints in 500+ patients for regulatory approval
FDA/EMA approved cancer vaccines available for standard clinical use